Allogene Therapeutics Inc - ALLO Net Assets per Single Share

Graphic logo of Allogene (ALLO)

Allogene Therapeutics (ALLO) management maintains an impeccable reputation within the scientific community, focusing on the final stages of clinical trials. Current price action on GURU.Markets, where the indicator stands at 1.25, reflects the movement of shares for this pioneer in the development of affordable donor-cell-based therapies. This biotech firm relies on a non-cyclical development model that is entirely independent of inflationary processes or consumer demand.

ALLO: Allogene Therapeutics Inc Net Asset Value per Share 07/04/2022 - 10/27/2026

allogene.com - analytical breakdowns and key metrics (ALLO)

- price and consensus price forecast:
Price Chart Allogene Therapeutics Inc|ALLO - Price Target Chart
- market capitalization data:
Market Value Allogene Therapeutics|ALLO - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Allogene|ALLO - Total Stockholders' Equity|Market Value to Book Value Ratio allogene.com|ALLO - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Allogene Therapeutics|ALLO - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Allogene|ALLO - Company Cumulative Debt|Debt to Book Capitalization Ratio Allogene Therapeutics
Fundamental company valuation:ALLO - Allogene Therapeutics Inc
Flagship merchandise of Allogene

Book value per share represents the net accounting equity divided by the number of securities, which determines the intrinsic value of assets minus all liabilities. By analyzing the historical book value per share, an investor can assess the financial margin of safety for Allogene Therapeutics (ALLO) against the binary risks of developing specialized CAR-T therapies and the dependence on clinical trial outcomes.

Competitor analysis for Allogene Therapeutics

LEGN - Net Assets per Single Share|SANA: Net Assets per Single Share|Net Assets per Single Share AUTL|RNAC (selectabio.com) - Net Asset Value per Share|Net Assets per Single Share CLLS (Cellectis SA)|Net Asset Value per Share CRBU|Net Assets per Single Share Instil Bio, Inc TIL|Equity per Share genenta.com (GNTA)|Century Therapeutics, Inc. - Book Value per Share|Jasper Therapeutics Inc - Accounting Value per Share|SNTI (Senti Biosciences Inc) - Net Assets per Single Share|ADAP: Net Asset Value per Share|cero.bio (CERO) - Net Assets per Single Share|TCRT (Alaunos Therapeutics, Inc.) - Net Assets per Single Share|Net Assets per Single Share ACHL (Achilles Therapeutics PLC)|Net Asset Value per Share cargo-tx.com|PSTX: Book Value per Share|Book Value of One Share 2seventy bio Inc. TSVT|GRCL: Accounting Value per Share